Dyne Therapeutics launches phase 3 trial for DM1 treatment

We’ve got our first full and official look at the OnePlus 15T — and it’s stretching the definition of ‘small screen king’

Stifel cuts RxSight stock price target to $9 on revenue guidance

Microsoft warns ClickFix attacks targeting Windows Terminal to trick users into running malware

There’s a strong case for AI and crypto—but you have to squint to see it